References in periodicals archive ?
We assessed serological tests of HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, and anti-HCV using Architect chemiluminescent enzyme immunoassays (Abbott Architect i system).
The most recent follow-up data for the patient is available at 2 years and 7 months from the acute episode, with the patient being in inactive HBsAg carrier state, (3) with liver function parameters remaining normal, still positive for HBsAg, but with undetectable HBV-DNA, negative HBeAg and positive HBeAb.
As busy diagnostic laboratories need to interpret all marker combinations, 7 of the 8 groups were included in the breakdown of extended marker results (HBeAg, HBeAb and HBcIM).
Patients who undergo seroconversion from HBeAg to HBeAb during lamivudine therapy may experience long-term remission, even after withdrawal of drug.
Among them, 16 patients were inactive HBsAg carrier with HBsAg [sup]+, HBeAb [sup]+, HBcAb [sup]+, and normal ALT; 1 patient was chronic HBV carrier with HBsAg [sup]+, HBeAg [sup]+, HBcAb [sup]+, normal ALT, and an HBV DNA load of 1.
The fact that parameters such as HBsAb, Anti HBc IgG core total, HBeAg, HBeAb, AST, and ALT were not examined, and that the cases were not classified in detail (as acute or chronic hepatitis, active or inactive HBsAg carrier) are limitations of the study.
Some patients who undergo seroconversion to HBeAb maintain elevated ALT and HBV DNA levels and remain in, or revert to, an immune-active phase, sometimes called the immune escape phase of HBV disease.
Acronyms browser ?
Full browser ?
- HBEAG-binding protein 2-binding protein C
- HBEBP2-binding protein C